In a phase II trial of dabrafenib plus trametinib for BRAF-mutated stage IV NSCLC patients who have prior history of chemotherapy, 57 patients showed ORR (primary endpoint) of 66.7% and mPFS of 9.7 months [15]. This evidence concerns the gene BRAF and non-small cell lung carcinoma.